Thursday October 17, 2019

Scientists Facilitate The Regulatory Process For Herbal Drugs

A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.

0
//
drugs
Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export. Pixabay

Council of Scientific and Industrial Research’s constituent laboratory, the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, and the Indian Pharmacopeia Commission (IPC), Ghaziabad, have joined hands to facilitate the regulatory process for biosimilars and herbal drugs, as per a statement here on Sunday.

The scope of the memorandum of understanding (MoU) signed between CSIR-CCMB and the IPC is the development of biopharmaceutical reference standards and impurities therein, development of monographs for important Monoclonal Antibodies and identification of herbal drugs based on DNA Barcode analysis, a CCMB statement said.

Use of biologics – biological products that function as drugs against diseases – also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India.

lab

Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added. Pixabay

A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.

Emergence of biopharmaceutical drugs as a preferred choice for therapy over conventional pharma drugs, requires concerted efforts by various sectors within the country towards production, characterisation and validation of indigenously developed products, the CCMB said.

The agreement was signed by CSIR-CCMB Director Rakesh Mishra and IPC’s Secretary-cum-Scientific Director G.N. Singh.

This collaboration, which has come into force with immediate effect, is very important in the current scenario owing to the increase in use of therapeutic proteins and herbal drugs for various diseases, the statement said.

scientist
Use of biologics – biological products that function as drugs against diseases – also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India. Pixabay

Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export.

Also Read: When You Engage in ‘Hedonic Consumption’? Read Here To Find Out

This collaborative project will be executed at par with pharmacopeia standards of other countries, it said.

Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added. (IANS)

Next Story

Google Partners Social Alpha to Support Social Impact Start-ups in India

Google Developers Launchpad is a branch of Google that operates a global acceleration programme which helps start-ups around the world to grow

0
google
FILE - A woman walks past the logo for Google at the China International Import Expo in Shanghai, Nov. 5, 2018. VOA

Tata Trusts’ initiative Social Alpha said on Tuesday it has entered into a partnership with Google Developers Launchpad to support social impact start-ups in Indias growing start-up ecosystem.

The partnership – Social Alpha Powered by Google Developers Launchpad – is designed to help start-ups gain access to resources including expert mentors, tools, and methodologies for building businesses that can drive meaningful impact on the technology ecosystem.

This initiative will enable Social Alpha to create learning programmes based on information and resources aggregated from a select group of the world’s top accelerators.

Social Alpha will also access Google’s global network, insights from the company’s Silicon Valley-based start-up programmes and Google’s research and best practices on building businesses, products, and teams.

“As we continue to build and grow the lab-to-market ecosystem for high impact innovations in India, our portfolio companies need access to world class technologies especially in the areas of data science and machine learning,” Manoj Kumar, Founder and CEO of Social Alpha, said in a statement.

amazon
FILE – The Google logo is seen at a start-up campus in Paris, France, Feb. 15, 2018. VOA

“Our partnership with the Google Developers Launchpad program will address this gap, and help unlock the immense potential that resides in these start-ups,” Kumar said.

This partnership will focus on supporting start-ups that have the potential and / or are already incorporating Artificial Intelligence and Machine Learning Technologies in their work.

Also Read: Social Robots Can Now be Conflict Mediators: Study

“Google Developers Launchpad doesn’t take an equity stake in accelerator portfolio start-ups, but instead focuses on developing companies and their ecosystems over the long term,” said Kevin O’Toole, Google’s Head of International Growth for Launchpad.

Google Developers Launchpad is a branch of Google that operates a global acceleration programme which helps start-ups around the world to grow. (IANS)